These findings suggest that dysregulated lipid composition in APOE4/4 BDEVs, especially enrichment of FFA 18:2, may drive tau pathology, potentially exacerbating neuroinflammation and disease progression in APOE4 AD cases. The gene discussed is MAPT; the disease is Alzheimer disease.